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Abstract
Background: Heat shock protein 90 (Hsp90) overexpression has been implicated in breast
carcinogenesis, with putative prognostic and therapeutic implications. The purpose of this study is to
evaluate the immunohistochemical expression of Hsp90 and to examine whether Hsp90 expression is
associated with estrogen receptor alpha (ER-alpha) and beta (ER-beta) immunostaining in lobular neoplasia
(LN) of the breast.
Methods: Tissue specimens were taken from 44 patients with LN. Immunohistochemical assessment of
Hsp90, ER-alpha and ER-beta was performed both in the lesion and the adjacent normal breast ducts and
lobules; the latter serving as control. As far as Hsp90 evaluation is concerned: i) the percentage of positive
cells, and ii) the intensity was separately analyzed. Additionally, the Allred score was adopted and
calculated. Accordingly, Allred score was separately evaluated for ER-alpha and ER-beta. The intensity was
treated as an ordinal variable-score (0: negative, low: 1, moderate: 2, high: 3). Statistical analysis followed.
Results: Hsp90 immunoreactivity was mainly cytoplasmic in both the epithelial cells of normal breast
(ducts and lobules) and LN. Some epithelial cells of LN also showed nuclear staining, but all the LN foci
mainly disclosed a positive cytoplasmic immunoreaction for Hsp90. In addition, rare intralobular
inflammatory cells showed a slight immunoreaction. The percentage of Hsp90 positive cells in the LN areas
was equal to 67.1 ± 12.2%, whereas the respective percentage in the normal adjacent breast tissue was
69.1 ± 11.6%; the difference was not statistically significant. The intensity score of Hsp90 staining was 1.82
± 0.72 in LN foci, while in the normal adjacent tissue the intensity score was 2.14 ± 0.64. This difference
was statistically significant (p = 0.029, Wilcoxon matched-pairs signed-ranks test). The Hsp90 Allred score
was 6.46 ± 1.14 in the LN foci, significantly lower than in the normal adjacent tissue (6.91 ± 0.92, p = 0.049,
Wilcoxon matched-pairs signed-ranks test). Within the LN foci, the Hsp90 Allred score was neither
associated with ER-alpha, nor with ER-beta percentage.
Conclusion: Hsp90 was lower in LN foci both at the level of intensity and Allred score, a finding contrary
to what might have been expected, given that high Hsp90 expression is detected in invasive breast
carcinomas. Hsp90 deregulation does not seem to be a major event in LN pathogenesis.
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Heat shock proteins (Hsps) or stress proteins are one of
the most evolutionarily conserved classes of molecules to
play a fundamental role in the maintenance of cellular
homeostasis. Under normal conditions, they act as
"molecular chaperones", assisting protein folding, trans-
port and degradation. On the other hand, during stress
they prevent aggregation and promote refolding of dam-
aged proteins. Hsps are classified into several families,
named according to their approximate molecular weight
[1]. Hsp90 is one of the most abundant proteins in mam-
malian cells [2]. It forms several discrete subcomplexes,
each containing distinct groups of co-chaperones that
function in these folding pathways.
Elevated Hsp90 expression has been documented in
breast cancer [3-5], contributing to the proliferative activ-
ity of breast cancer cells. In parallel, Hsp90 overexpression
has been interpreted as a means through which breast
cancer cells become resistant to various stress stimuli [5].
Interestingly, a recent study has revealed that higher
Hsp90 expression may be a marker of poor disease prog-
nosis [6]. It has also been suggested that these family pro-
teins are directly involved in the drug resistance of breast
cancer cells [7,8]. As a result of the multifaceted Hsp
involvement in breast cancer, pharmacological inhibition
of Hsps appears to provide therapeutic opportunities in
the field of cancer treatment [9-13]; 17-allylamino, 17-
demethoxygeldanamycin (17-AAG), the first Hsp90
inhibitor to undergo clinical development, has yielded
promising results [14,15].
However, there is no data reporting on the Hsp expression
in response to precancerous breast lesions and lobular
neoplasia in particular. According to the most recent
WHO classification, lobular neoplasia (LN) includes the
designations atypical lobular hyperplasia (ALH) and lob-
ular carcinoma in situ (LCIS) and refers to the entire spec-
trum of atypical epithelial proliferation originating in the
terminal duct-lobular unit, with or without involvement
of ducts [16]. Nowadays, it is widely known that LN rep-
resents a risk factor and a non-obligatory precursor for the
subsequent development of invasive carcinoma in either
breast, of either ductal or lobular type [17].
Hsp90 interacts with a complex of proteins which play key
roles in breast neoplasia. This complex includes estrogen
receptors (ER), tumor suppressor p53 protein, angiogen-
esis transcription factor HIF-1alpha, antiapoptotic kinase
Akt, Raf-1 MAP kinase and a variety of receptor tyrosine
kinases, such as erbB2 (reviewed in [14]. Among these
proteins, examination of ERs seems an appropriate point
to begin with, given the absolute lack of data concerning
LN; indeed, in the context of breast carcinogenesis, ERs
play a pivotal role (reviewed in [18]). Not being affected
by mutations, ERs represent a molecule with particular
clinical and therapeutic importance [19].
Concerning ER expression in LN, ER receptor positivity is
a well-established feature of lobular carcinoma in situ
[20,21]. Interestingly, our previous work in LN has dem-
onstrated a significant ER-alpha upregulation and ER-beta
downregulation in LN; regarding the ER-alpha/ER-beta
ratio, this shift in favor of the numerator may represent a
relative proliferative advantage of LN cells. Noticeably
though, the two parallel molecular events seemed to
exhibit a mutually limiting behavior, according to which
greater increase in ER-alpha expression was associated
with smaller reduction in ER-beta expression and vice
versa [22].
To date, there are no data examining Hsp90 in combina-
tion with ER-alpha and ER-beta status in patients whose
main lesion is LN. Interestingly, it is tempting to speculate
that, given the importance of both ERs and Hsp90, their
simultaneous examination may have implications for the
relative risk associated with these borderline lesions and
suggest opportunities for chemoprevention. To our
knowledge, this is the first study to focus on the immuno-
histochemical expression of Hsp90 and estrogen receptors
alpha and beta in LN cases; apart from the immunohisto-
chemical expression of Hsp90 by itself, special attention
was paid to the ER-Hsp90 association.
Methods
Formalin-fixed, paraffin-embedded tissue specimens were
taken from 44 patients with LN. The patients' age at oper-
ation ranged between 34 and 67 (median age: 48 years).
The diagnosis of LN was established by vacuum-assisted
breast biopsy or by excisional breast biopsy. Cases of LN
coexisting with atypical ductal hyperplasia, ductal carci-
noma in situ, invasive lobular carcinoma or invasive duc-
tal carcinoma were excluded.
Hsp90 was immunohistochemically detected using the
monoclonal antibody Hsp90 (clone JPB24) (Novocastra
supplied by Menarini), while ER-alpha and ER-beta recep-
tors were immunohistochemically detected with the com-
mercially available ER6f-11 and ER-beta (clone EMRO2)
(Novocastra supplied by Menarini) antibodies. All were
visualized using an avidin-biotin detection system. Anti-
gen retrieval was achieved in 0.001 M citrate buffer (pH =
6.0) at 85°C for 18 h. Immunohistochemical assessment
of Hsp90, ER-alpha and ER-beta was performed both in
the lesion and the adjacent normal breast ducts and lob-
ules; the latter serving as control. Negative controls were
assessed by omitting the primary antibody.
As far as Hsp90 evaluation is concerned: i) the percentage
of positive cells, and ii) the intensity was separately ana-Page 2 of 7
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culated; due to the lack of scoring system taking
simultaneously into account both intensity and percent-
age of Hsp90 staining.
Accordingly, Allred score was separately evaluated for ER-
alpha and ER-beta. In addition, to assess the clinical rele-
vance of ER-alpha and ER-beta expression, cases were des-
ignated as negative (0%), equivocal (less than 10%) and
positive (≥ 10%), as presented elsewhere [23,24].
In all cases, the area of maximum staining intensity was
preselected on each slide and a minimum of 100 cells
were evaluated in the designated area. The immunohisto-
chemical evaluation was performed independently by two
consultant histopathologists (AN and AL).
The intensity was treated as an ordinal variable-score (0:
negative, low: 1, moderate: 2, high: 3). Statistical analysis
was performed with STATA 8.0 statistical software (Stata
Corporation, College Station, TX, USA). Due to deviation
from the normal distribution, non-parametric statistics
were chosen. The statistic performed in each case is men-
tioned in parentheses in the text.
Informed consent was obtained by all participants in this
study. This study has been approved by the local Ethics
Committee, in compliance to the Helsinki Declaration.
Results
Hsp90 immunoreactivity was mainly cytoplasmic in both
the epithelial cells of normal breast (ducts and lobules)
(figure 1) and LN (figure 2). Some epithelial cells of LN
also showed nuclear staining (figure 2), but all the LN foci
mainly disclosed a positive cytoplasmic immunoreaction
for Hsp90; the percentage of these positive cells and the
staining intensity were evaluated. In addition, rare intral-
obular inflammatory cells showed a slight immunoreac-
tion (figure 1). As far as ER is concerned, moderate to
strong nuclear ER-alpha (figure 3) and ER-beta (figure 4)
immunoreactivity was detected in epithelial cells of nor-
mal ducts and lobules and in LN. Additionally, ER immu-
nostaining has been observed on some lymphocytes.
The percentage of Hsp90 positive cells in the LN areas was
equal to 67.1 ± 12.2%, whereas the respective percentage
in the normal adjacent breast tissue was 69.1 ± 11.6%; the
difference was not statistically significant (p = 0.679, Wil-
coxon matched-pairs signed-ranks test).
The intensity score of Hsp90 staining was 1.82 ± 0.72 in
LN foci, while in the normal adjacent tissue the intensity
score was 2.14 ± 0.64. This difference was statistically sig-
nificant (p = 0.029, Wilcoxon matched-pairs signed-ranks
test). The Hsp90 Allred score was 6.46 ± 1.14 in the LN
foci, significantly lower than in the normal adjacent tissue
(6.91 ± 0.92, p = 0.049, Wilcoxon matched-pairs signed-
ranks test). The two statistically significant findings are
depicted in Figure 5.
Concerning ERs, it should be stressed that all LN cases
were above the 10% positivity threshold both regarding
ER-alpha and ER-beta; as a result, all LN cases were desig-
nated as alpha positive/beta positive. The more elaborate
Strong cytoplasmic HSP90 immunoreactivity in the epithelial cells of lobule with slight dilation f the aciniFigure 1
Strong cytoplasmic HSP90 immunoreactivity in the 
epithelial cells of lobule with slight dilation of the 
acini. Rare inflammatory cells are slightly immunoreacted, as 
well (×100).
Moderate HSP90 cytoplasmic immunoreaction in the epithe-lial c lls of LNFigure 2
Moderate HSP90 cytoplasmic immunoreaction in 
the epithelial cells of LN. Note the nuclear imunoreac-
tion of some epithelial cells in the upper half of the figure 
(×200).Page 3 of 7
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results previously reported [22]; in LN the Allred score for
ER-alpha was higher than in the adjacent normal breast
ducts and lobules (6.78 ± 1.19 vs. 6.33 ± 1.28; p = 0.047,
Wilcoxon matched-pairs signed-ranks test), but lower as
far as ER-beta was concerned (6.45 ± 1.18 vs. 7.22 ± 0.69;
p < 0.001, Wilcoxon matched-pairs signed-ranks test)
Within the LN foci, the Hsp90 Allred score was neither
associated with ER-alpha (Spearman's rho = -0.039, p =
0.823), nor with ER-beta percentage (Spearman's rho = -
0.027, p = 0.878). Similarly, with regard to percentage and
intensity no statistically significant associations were doc-
umented between Hsp90 and ER-alpha, ER-beta. Like-
wise, the Hsp90 Allred score was neither associated with
ER-alpha (Spearman's rho = -0.178, p = 0.267), nor with
ER-beta percentage (Spearman's rho = -0.012, p = 0.943)
within the normal adjacent tissue. Similarly, no statisti-
cally significant associations existed between the constitu-
ents.
In an attempt to evaluate mutually limiting phenomena
(cf. [22]), the difference in Allred score for Hsp90 [Allred
score in LN - Allred score in the normal adjacent tissue]
was comparatively assessed with the respective differences
for ER-alpha and ER-beta. However, no statistically signif-
icant associations existed (Spearman's rho = 0.100, p =
0.561 for ER-alpha, and Spearman's rho = -0.054, p =
0.757 for ER-beta).
Discussion
In comparison to the adjacent normal breast lobules and
ducts, Hsp90 expression was lower in LN foci both at the
level of intensity and Allred score. This finding seems con-
trary to what might have been expected, as it is widely
accepted that LN represents a precursor lesion and that
Hsp90 overexpression is detected in invasive breast carci-
nomas [4,6]. For the optimal interpretation of our results,
it should be kept in mind that LN is a non-obligatory pre-
cursor of breast cancer. In other words, the molecular
events therein may be self-limiting and may not necessar-
ily reflect those more extensive in invasive breast cancer.
In addition, LN lesions are benign lesions containing cells
not yet subject to the stresses occurring in invasive breast
cancer and thus a stress response seems not to have been
triggered at that neoplastic phase. On the other hand, the
present findings may indicate that the relative prolifera-
tion advantage in LN cells is an Hsp90-independent proc-
ess.
Noticeably, Hsp90 levels (as reflected both upon the per-
centage and staining intensity) were not associated with
ER-alpha and ER-beta status. This seems intriguing, as
Hsp90 is closely associated with the ER receptor signaling
pathway, playing an essential role in the stability and
function of steroid hormone receptors [25]. Indeed, in
vitro evidence in the literature actively implicates Hsp90 in
the regulation of ER expression. More specifically, it has
been suggested that Hsp90 protects ER-beta against pro-
teasomal degradation [26]; accordingly, Hsp90 inhibitors
have been shown to result in proteasome-mediated degra-
dation of ERs (reviewed in [14]).
Worthy of note, in the present study the above ER-Hsp90
association data are not confirmed at the level of immu-
nohistochemical expression in LN. Interestingly, the lack
of ER-Hsp90 association pertained to both LN and adja-
Immunohistochemical nuclear expression of ER-alpha in LN lesions (×100)Figure 3
Immunohistochemical nuclear expression of ER-
alpha in LN lesions (×100).
Immunohistochemical nuclear expression of ER-beta in LN lesions (×100)Figure 4
Immunohistochemical nuclear expression of ER-beta 
in LN lesions (×100).Page 4 of 7
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that LN represents a condition maintaining regulatory
mechanisms present in the normal status, thereby suggest-
ing that ER up-regulation and expression variability seem
not to be associated with Hsp90 perturbations at the con-
text of LN. Nevertheless, the inability to document the ER-
Hsp90 association may be partly due to the method per-
formed (i.e. immunohistochemistry); quantitative meth-
ods might be more sensitive regarding this association.
To date, studies have examined Hsp90 status in breast
cancer [4-6,8] without specifically focusing on lobular
lesions and carcinomas. Thus, it remains unclear whether
the herein documented results are indicative per se of the
status in lobular carcinogenesis or in precursor lesions in
general. Undoubtedly, further studies exclusively based
on invasive lobular carcinomas are essential to extrapolate
the present findings onto the continuum of lobular cancer
pathogenesis. Whether ER- Hsp90 independence disap-
pears in invasive lobular carcinoma, remains yet to be
clarified.
The exclusive examination of LN lesions is a distinct
advantage of this study. However, it was not without its
technical limitations. More specifically, as mentioned
above, the lack of an automated quantitative procedure
may have clouded some associations. Notwithstanding,
Hsp90 downregulation is not contestable given its clear
expression in a relatively less sensitive assessment. To
ensure the objectivity of the assessment, the percentage
and intensity were assigned by two independent patholo-
gists blind to one another's results.
In our cases, some epithelial cells of LN foci showed
nuclear Hsp90 localization. This finding has already been
reported in invasive breast carcinomas and has been cor-
related with MHC class I expression [27].
Conclusion
In conclusion, it can be said that Hsp90 expression was
lower in LN foci both at the level of intensity and Allred
score, a finding contrary to what might have been
expected, given that high Hsp90 expression is detected in
Hsp90 intensity and Allred scores (mean ± SE) in LN lesions and normal adjacent breast tissueFigure 5
Hsp90 intensity and Allred scores (mean ± SE) in LN lesions and normal adjacent breast tissue. Both scores are 
significantly lower in LN lesions (cf. Results).Page 5 of 7
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seem to be a major event in LN pathogenesis. As regards
LN, Hsp90 does not seem to be associated with estrogen
receptor status. Further studies adopting quantitative pro-
cedures and assessing mRNA levels are needed. This study
may prompt other studies evaluating Hsp90 expression in
invasive lobular carcinoma as well as other precursor
lesions.
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